NEFL and Brain atrophy: The phase II clinical trial examining Tilavonemab did not result in significant decreases in CDR-SB, secondary outcome measures such as ADAS-Cog14, RBANS, MMSE, FAQ, and ADCS-ADL, nor led to protection from brain atrophy or neurofilament light (NfL) [167].